scholarly journals Plasma Brain-Derived Neurotrophic Factor (BDNF) Concentration and BDNF/TrkB Gene Polymorphisms in Croatian Adults with Asthma

2020 ◽  
Vol 10 (4) ◽  
pp. 189
Author(s):  
Katherina B. Sreter ◽  
Sanja Popovic-Grle ◽  
Marina Lampalo ◽  
Marcela Konjevod ◽  
Lucija Tudor ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Gene Polymorphisms ◽  
Brain Derived Neurotrophic Factor ◽  
Asthma Severity ◽  
Normal Lung ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Individuals ◽  
Eosinophilic Asthma ◽  
Aspirin Sensitivity ◽  
Asthma Patients

Brain-derived neurotrophic factor (BDNF) and its tropomyosin-related kinase B (TrkB) receptor might contribute to normal lung functioning and immune responses; however, their role in asthma remains unclear. Plasma BDNF concentrations, as well as BDNF and NTRK2 (TrkB gene) polymorphisms, were investigated in 120 asthma patients and 120 healthy individuals using enzyme-linked immunosorbent assay and polymerase chain reaction, respectively. The genotype and allele frequencies of BDNF Val66Met (rs6265) and NTRK2 rs1439050 polymorphisms did not differ between healthy individuals and asthma patients, nor between patients grouped according to severity or different asthma phenotypes. Although plasma BDNF concentrations were higher among healthy subjects carrying the BDNF Val66Met GG genotype compared to the A allele carriers, such differences were not detected in asthma patients, suggesting the influences of other factors. Plasma BDNF concentration was not affected by NTRK2 rs1439050 polymorphism. Asthma patients had higher plasma BDNF concentrations than control subjects; however, no differences were found between patients subdivided according to asthma severity, or Type-2, allergic, and eosinophilic asthma. Higher plasma BDNF levels were observed in asthma patients with aspirin sensitivity and aspirin-exacerbated respiratory disease. These results suggest that plasma BDNF may serve as a potential peripheral biomarker for asthma, particularly asthma with aspirin sensitivity.

scholarly journals Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation

2020 ◽  
Vol 10 ◽  
pp. 204512532097379
Author(s):  
Wei Zheng ◽  
Yan-Ling Zhou ◽  
Cheng-Yu Wang ◽  
Xiao-Feng Lan ◽  
Bin Zhang ◽  
...  
Keyword(s):  
Suicidal Ideation ◽  
Correlation Analysis ◽  
Immunosorbent Assay ◽  
Neurotrophic Factor ◽  
Plasma Levels ◽  
Rating Scale ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depressed Patients ◽  
Over Time

Background: This study is the first to examine the association between plasma levels of brain-derived neurotrophic factor (BDNF) and the antisuicidal effects of repeated ketamine infusions in depressed patients with suicidal ideation. Methods: Fifty-seven depressed patients with suicidal ideation received six ketamine infusions (0.5 mg/kg) during a 12 days period. Suicidality was measured with the Scale for Suicidal Ideations (SSI-part 1), item 10 of the Montgomery–Åsberg Depression Rating Scale (MADRS), and item 3 of the Hamilton Depression Rating Scale (HAMD) at baseline, 1 day after the first infusion (1 day), 1 day after the sixth infusion (13 days), and at 2 weeks after the last infusion (26 days). Plasma levels of BDNF were measured by enzyme-linked immunosorbent assay at baseline, 13 days, and 26 days. Results: Overall, 46 (80.7%) depressed patients with suicidal ideation had an antisuicidal response at 13 days. Despite a significant reduction in suicidal symptoms over time, no changes in plasma levels of BDNF were found after ketamine treatment when compared with baseline. Correlation analysis showed that no significant association was observed between the plasma levels of BDNF and the changes in the severity of suicidal symptoms as measured by SSI-part 1, item 10 of the MADRS, or item 3 of the HAMD at 1 day, 13 days, and 26 days (all p < 0.05). Conclusion: Our results indicated that plasma levels of BDNF may not serve as a biomarker for determining the antisuicidal effects of six ketamine infusions in depressed patients with suicidal ideation.

No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial

2015 ◽  
Vol 28 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Ulla Knorr ◽  
Pernille Koefoed ◽  
Mia H. Greisen Soendergaard ◽  
Maj Vinberg ◽  
Ulrik Gether ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Whole Blood ◽  
Neurotrophic Factor ◽  
Messenger Rna ◽  
Randomised Trial ◽  
Significant Negative Correlation ◽  
Brain Derived Neurotrophic Factor ◽  
Healthy Individuals ◽  
Bdnf Mrna ◽  
Significant Difference

ObjectiveBrain-derived neurotrophic factor (BDNF) seems to play an important role in the course of depression including the response to antidepressants in patients with depression. We aimed to study the effect of an antidepressant intervention on peripheral BDNF in healthy individuals with a family history of depression.MethodsWe measured changes in BDNF messenger RNA (mRNA) expression and whole-blood BDNF levels in 80 healthy first-degree relatives of patients with depression randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks.ResultsWe found no statistically significant difference between the escitalopram and the placebo group in the change in BDNF mRNA expression and whole-blood BDNF levels. Post hoc analyses showed a statistically significant negative correlation between plasma escitalopram concentration and change in whole-blood BDNF levels in the escitalopram-treated group.ConclusionThe results of this randomised trial suggest that escitalopram 10 mg has no effect on peripheral BDNF levels in healthy individuals.

Association Analysis of Brain-Derived Neurotrophic Factor Gene Polymorphisms in Asthmatic Families

2009 ◽  
Vol 149 (4) ◽  
pp. 343-349 ◽  
Author(s):  
Aleksandra Szczepankiewicz ◽  
Matthew J. Rose-Zerilli ◽  
Sheila J. Barton ◽  
Stephen T. Holgate ◽  
John W. Holloway
Keyword(s):  
Association Analysis ◽  
Neurotrophic Factor ◽  
Gene Polymorphisms ◽  
Brain Derived Neurotrophic Factor ◽  
Factor Gene

scholarly journals Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls

BJPsych Open ◽  
2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Nanna Aagaard Petersen ◽  
Marc Østergaard Nielsen ◽  
Klara Coello ◽  
Sharleny Stanislaus ◽  
Sigurd Melbye ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Newly Diagnosed ◽  
First Degree Relatives ◽  
Duration Of Illness ◽  
And Gender ◽  
Medication Status

Background Brain-derived neurotrophic factor (BDNF), which facilitates neuroplasticity and synaptogenesis, may be decreased in bipolar disorder, but has not been systematically investigated in people with newly diagnosed bipolar disorder and unaffected first-degree relatives. Aims To compare BDNF levels in patients with newly diagnosed bipolar disorder, their unaffected first-degree relatives and healthy controls. Method The study investigated plasma BDNF levels in patients (n = 371) with newly diagnosed bipolar disorder, their unaffected first-degree relatives (n = 98) and healthy controls (n = 200) using enzyme-linked immunosorbent assay. We further investigated associations between BDNF levels and illness-related variables and medication status. Results BDNF levels were found to be 22.0% (95% CI 1.107–1.343) higher in patients with bipolar disorder compared with healthy controls (P < 0.001) and 15.6% higher in unaffected first-degree relatives compared with healthy controls (95% CI 1.007–1.327, P = 0.04), when adjusting for age and gender. Further, BDNF levels were positively associated with duration of illness at a trend level (P = 0.05), age (P = 0.001) and use of anti-epileptic medication (P = 0.05). Conclusions These findings suggest that BDNF levels are not decreased in the early stages of bipolar disorder and in unaffected first-degree relatives contrasting with prior findings during later stages of the illness.

scholarly journals Ramadan Fasting in Germany (17–18 h/Day): Effect on Cortisol and Brain-Derived Neurotrophic Factor in Association With Mood and Body Composition Parameters

2021 ◽  
Vol 8 ◽  
Author(s):  
Amin Riat ◽  
Abdulhadi Suwandi ◽  
Samaneh Khoshandam Ghashang ◽  
Manuela Buettner ◽  
Luqman Eljurnazi ◽  
...  
Keyword(s):  
Body Composition ◽  
Neurotrophic Factor ◽  
Venous Blood ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Intermittent Fasting ◽  
Serum Samples ◽  
Ramadan Fasting ◽  
Insulin Growth Factor ◽  
Health Related

Ramadan fasting (RF) is a type of diurnal intermittent fasting. Previous studies reported the benefits of RF in healthy subjects on mood and health related to quality of life (QoL). Cortisol and brain-derived neurotrophic factor (BDNF) have been shown to play a role in mood, body composition parameters, and health-related QoL. This study aimed at elucidating the mechanism of the benefit of RF, particularly cortisol and BNDF and their association with mood and QoL. Insulin growth factor-1 (IGF-1), interleukin (IL)-8, matrix metalloproteinase (MMP)-9, and myoglobin were determined. Thirty-four healthy men and women were recruited. Serum from peripheral venous blood samples was collected at five time points: 1 week before RF (T1); mid of RF (T2), last days of RF (T3), 1 week after RF (T4), and 1 month after RF (T5). The amounts of biological mediators in the serum samples were determined by enzyme-linked immunosorbent assay (ELISA) and Luminex assays. BDNF and cortisol significantly decreased at T3 (p &lt; 0.05) and T4 (p &lt; 0.001) compared to T1, respectively. It seems the benefits of RF for mood-related symptoms are mediated by different biological mediators, particularly cortisol and BDNF.

Sign in / Sign up

Export Citation Format

Share Document